Publisher · Editorial standards
PeptideStat guides are researched and maintained by the PeptideStat Editorial Team — a collective byline for work produced under one sourcing standard. We do not invent individual medical credentials for marketing purposes.
Our job is readable peptide literacy: mechanisms, human evidence (or its absence), regulatory status, safety uncertainty, vendor documentation quality and practical comparisons — without turning research compounds into DIY prescriptions.
Process over personality. Every money page should show the same discipline whether the topic is an approved GLP-1 or a research-only recovery peptide.
01
Each guide starts from a real search intent (what it is, evidence, dosage in trials, comparison, safety) — not a keyword dump.
02
Approved drug, investigational, research-only or compounding context. We separate human data from animal-only claims early.
03
Trial design, N, dose, outcomes and limitations when available. Missing human data is stated as missing.
04
Guides carry published and last-reviewed dates. Material regulatory or trial updates trigger a rewrite, not a silent tweak.
When sources conflict, higher tiers win. Marketing never outranks a label or a trial.
Primary
Peer-reviewed trials, FDA labels / USPIs, ClinicalTrials.gov records, regulatory briefing materials.
Secondary
Systematic reviews, high-quality narrative reviews, manufacturer trial summaries when methods are transparent.
Market data
Dated vendor catalog prices, public COAs and policies we can open ourselves — not review-site scores as proof.
Not treated as evidence
Anonymous forum dosing, TikTok protocols, vendor marketing copy, unsourced “stack” charts.
Some pages include affiliate links. Commissions may apply if you buy through them. Partner placement never changes regulatory status labels, evidence summaries or safety caveats. Details live in our disclaimer and editorial policy.
Vendor market pages use dated price and documentation snapshots. See the 2026 vendor transparency report for methodology readers can inspect.
If you find a factual error, outdated label claim or broken primary source, email admin@peptidestat.com. Material corrections update the page and the last-reviewed date.
Nothing on PeptideStat is medical advice. Many peptides discussed are investigational or research-only. Decisions about health care belong with a qualified clinician.
peptide-basics
Unopened bacteriostatic water lasts until its printed expiry at room temperature. Once the vial is punctured, standard practice is to date it and discard within 28 days. That window covers the diluent, not the peptide mixed with it.
bpc-157
Oral BPC-157 is marketed for convenience and gut claims; injectables dominate recovery forums. Both rest on preclinical data — not proven human route equivalence.
glp-1
CagriSema is Novo Nordisk’s investigational amylin + GLP-1 combination. Trial averages look strong, but it is not approved and is not a DIY stack of research vials.
peptide-buying
A dated audit of NOVA Labs covering public batch records, third-party lab links, UAE and GCC delivery, AED pricing and what PeptideStat did not verify.
bpc-157
Headlines said FDA approved BPC-157. The real story is a non-binding PCAC vote on the 503A compounding list, not NDA approval, not a sports-medicine label, not proof it works in humans.
glp-1
GLP-1 pancreatitis risk is real enough to appear in labels, but rare enough that trials and meta-analyses need careful interpretation.
glp-1
Semaglutide and NAION is now a real pharmacovigilance topic, but the absolute risk appears low and the evidence is mostly observational.
glp-1
Orforglipron is the oral small-molecule GLP-1 sold as Foundayo. It is not a peptide, but it matters for peptide readers because it changes the oral GLP-1 comparison.
glp-1
Pemvidutide is an investigational GLP-1/glucagon dual agonist peptide with human MASH and liver-fat data. The strongest claim is MASH resolution signal, not proven fibrosis benefit.
glp-1
The current Ozempic label includes a kidney-outcome indication for adults with type 2 diabetes and chronic kidney disease. FLOW is the main trial to understand, not a general kidney-health claim.
glp-1
Zepbound is FDA approved for moderate-to-severe obstructive sleep apnea in adults with obesity. The evidence is strong for that population, but it is not a replacement for diagnosis or PAP planning.
glp-1
Tirzepatide labels give a specific backup contraception window for oral contraceptives. Semaglutide evidence is different, but vomiting, diarrhea and pregnancy planning still matter.